Grants per year
Personal profile
Training Experience
| 1996 | Fellowship, Wayne State University |
| 1999 | Internship, Wayne State University |
| 2002 | Residency, University of Chicago Hospitals |
| 2004 | Fellowship, University of Chicago Hospitals |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Medical Academy, Sofia, Bulgaria
… → 1991
Fingerprint
Dive into the research topics where Roumen Deltchev Balabanov is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #NMOSD-750: CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Balabanov, R. D. (PD/PI)
10/20/22 → 10/20/25
Project: Research project
-
Northwestern Multiple Sclerosis/Neuroimmunology Fellowship
Balabanov, R. D. (PD/PI)
National Multiple Sclerosis Society
7/1/23 → 6/30/24
Project: Research project
-
Northwestern Multiple Sclerosis/Neuroimmunology Fellowship
Balabanov, R. D. (PD/PI)
National Multiple Sclerosis Society
7/1/22 → 6/30/23
Project: Research project
-
Northwestern MS/Neuroimmunology fellowship proposal
Balabanov, R. D. (PD/PI)
National Multiple Sclerosis Society
7/1/21 → 6/30/22
Project: Research project
-
Prot#253MS201: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple S
Balabanov, R. D. (PD/PI)
1/22/21 → 1/21/22
Project: Research project
-
Cerebrovascular hemodynamics association with brain structure and function in Multiple Sclerosis
Duque, C., Mahin Rad, S., Sedaghat, S., Higgins, J., Milstead, A., Sargento-Freitas, J., Balabanov, R., Cohen, B. A. & Sorond, F. A., Nov 2024, In: Multiple Sclerosis and Related Disorders. 91, 105882.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder
Arellano, G., Loda, E., Chen, Y., Neef, T., Cogswell, A. C., Primer, G., Joy, G., Kaschke, K., Wills, S., Podojil, J. R., Popko, B., Balabanov, R. & Miller, S. D., Apr 1 2024, In: Brain. 147, 4, p. 1344-1361 18 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Multiple Sclerosis
Choudhury, N. & Balabanov, R., Jan 1 2024, Ferri's Clinical Advisor 2025: 5 Books in 1. Elsevier, p. 742-747.e2Research output: Chapter in Book/Report/Conference proceeding › Chapter
-
Case report: Use of granulocyte-colony stimulating factor as an immunomodulatory therapy in a patient with neuromyelitis optica spectrum disorder and comorbid immunodeficiency
Perez Giraldo, G. S., Graham, E. L., VanHaerents, S. & Balabanov, R., 2023, In: Frontiers in Neurology. 14, 1240356.Research output: Contribution to journal › Article › peer-review
Open Access -
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study (CNS Drugs, (2022), 36, 9, (977-993), 10.1007/s40263-022-00950-0)
Perumal, J., Balabanov, R., Su, R., Chang, R., Balcer, L. J., Galetta, S. L., Avila, R. L., Rutledge, D. & Fox, R. J., 2023, (Accepted/In press) In: CNS Drugs.Research output: Contribution to journal › Comment/debate › peer-review
Open Access1 Scopus citations
Datasets
-
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
Perumal, J. (Creator), Fox, R. J. (Creator), Balabanov, R. (Creator), Balcer, L. J. (Creator), Galetta, S. (Creator), Makh, S. (Contributor), Santra, S. (Contributor), Hotermans, C. (Creator) & Lee, L. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4534241, https://springernature.figshare.com/collections/Outcomes_of_natalizumab_treatment_within_3_years_of_relapsing-remitting_multiple_sclerosis_diagnosis_a_prespecified_2-year_interim_analysis_of_STRIVE/4534241
Dataset
-
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Perumal, J. (Creator), Balabanov, R. (Creator), Su, R. (Creator), Chang, R. (Creator), Balcer, L. (Creator), Galetta, S. (Creator), Campagnolo, D. I. (Creator), Avila, R. (Creator), Lee, L. (Creator), Rutledge, D. (Creator) & Fox, R. J. (Creator), Adis Journals, 2021
DOI: 10.6084/m9.figshare.14248406.v1, https://adisjournals.figshare.com/articles/media/Natalizumab_in_Early_Relapsing-Remitting_Multiple_Sclerosis_A_4-Year_Open-Label_Study/14248406/1
Dataset